It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARCT’s FA Score shows that 0 FA rating(s) are green whileKLAC’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARCT’s TA Score shows that 7 TA indicator(s) are bullish while KLAC’s TA Score has 5 bullish TA indicator(s).
ARCT (@Biotechnology) experienced а +9.20% price change this week, while KLAC (@Semiconductors) price change was -0.38% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.95%. For the same industry, the average monthly price growth was +32.23%, and the average quarterly price growth was +16.56%.
The average weekly price growth across all stocks in the @Semiconductors industry was +3.10%. For the same industry, the average monthly price growth was +11.99%, and the average quarterly price growth was -3.62%.
ARCT is expected to report earnings on Aug 11, 2025.
KLAC is expected to report earnings on Jul 24, 2025.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Semiconductors (+3.10% weekly)The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.
ARCT | KLAC | ARCT / KLAC | |
Capitalization | 378M | 96.1B | 0% |
EBITDA | -63.92M | 3.83B | -2% |
Gain YTD | -20.978 | 41.748 | -50% |
P/E Ratio | N/A | 35.99 | - |
Revenue | 131M | 9.67B | 1% |
Total Cash | 217M | 3.34B | 6% |
Total Debt | 42.7M | 6.08B | 1% |
ARCT | KLAC | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 14 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 63 | 10 | |
P/E GROWTH RATING 1..100 | 100 | 78 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ARCT's Valuation (50) in the Pharmaceuticals Major industry is in the same range as KLAC (50) in the Electronic Production Equipment industry. This means that ARCT’s stock grew similarly to KLAC’s over the last 12 months.
KLAC's Profit vs Risk Rating (14) in the Electronic Production Equipment industry is significantly better than the same rating for ARCT (100) in the Pharmaceuticals Major industry. This means that KLAC’s stock grew significantly faster than ARCT’s over the last 12 months.
KLAC's SMR Rating (100) in the Electronic Production Equipment industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that KLAC’s stock grew similarly to ARCT’s over the last 12 months.
KLAC's Price Growth Rating (10) in the Electronic Production Equipment industry is somewhat better than the same rating for ARCT (63) in the Pharmaceuticals Major industry. This means that KLAC’s stock grew somewhat faster than ARCT’s over the last 12 months.
KLAC's P/E Growth Rating (78) in the Electronic Production Equipment industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that KLAC’s stock grew similarly to ARCT’s over the last 12 months.
ARCT | KLAC | |
---|---|---|
RSI ODDS (%) | N/A | 2 days ago50% |
Stochastic ODDS (%) | 2 days ago80% | 2 days ago72% |
Momentum ODDS (%) | 2 days ago87% | 2 days ago75% |
MACD ODDS (%) | 2 days ago88% | 2 days ago73% |
TrendWeek ODDS (%) | 2 days ago83% | 2 days ago63% |
TrendMonth ODDS (%) | 2 days ago80% | 2 days ago74% |
Advances ODDS (%) | 2 days ago81% | 2 days ago70% |
Declines ODDS (%) | 21 days ago87% | 6 days ago63% |
BollingerBands ODDS (%) | 2 days ago90% | 2 days ago76% |
Aroon ODDS (%) | 2 days ago82% | 2 days ago79% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
EMSLX | 18.67 | 0.48 | +2.64% |
Shelton Emerging Markets Investor | |||
LGLQX | 47.46 | 0.93 | +2.00% |
Lord Abbett Growth Leaders R2 | |||
FGHMX | 115.22 | 2.00 | +1.77% |
Fidelity Advisor Communication ServicesC | |||
IEGAX | 23.47 | 0.35 | +1.51% |
Invesco EQV Intl Small Company A | |||
SCUVX | 27.14 | 0.37 | +1.38% |
Hartford Schroders US Small Cap Opps A |
A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with TRDA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then TRDA could also see price increases.
Ticker / NAME | Correlation To ARCT | 1D Price Change % | ||
---|---|---|---|---|
ARCT | 100% | +7.19% | ||
TRDA - ARCT | 52% Loosely correlated | +0.57% | ||
ABCL - ARCT | 51% Loosely correlated | +10.51% | ||
MRNA - ARCT | 50% Loosely correlated | +4.40% | ||
ALEC - ARCT | 49% Loosely correlated | +8.36% | ||
RGNX - ARCT | 49% Loosely correlated | +8.91% | ||
More |
A.I.dvisor indicates that over the last year, KLAC has been closely correlated with AMAT. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if KLAC jumps, then AMAT could also see price increases.
Ticker / NAME | Correlation To KLAC | 1D Price Change % | ||
---|---|---|---|---|
KLAC | 100% | +3.82% | ||
AMAT - KLAC | 93% Closely correlated | +4.78% | ||
LRCX - KLAC | 93% Closely correlated | +4.39% | ||
ASML - KLAC | 88% Closely correlated | +4.31% | ||
VECO - KLAC | 83% Closely correlated | +5.35% | ||
ENTG - KLAC | 81% Closely correlated | +7.58% | ||
More |